Parallel Advisors, LLC Rain Therapeutics Inc. Transaction History

Parallel Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 20, 2024	SELL	$0.82 - $1.42 $9,193 - $15,921	-11,212 Reduced 83.29%	2,250 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.42 $9,193 - $15,921	-11,212 Reduced 83.29%	2,250 $1,000
Q2 2023 May 20, 2024	BUY	$1.09 - $9.93 $1,090 - $9,930	1,000 Added 8.02%	13,462 $16,000
Q2 2023 Aug 04, 2023	BUY	$1.09 - $9.93 $1,090 - $9,930	1,000 Added 8.02%	13,462 $16,000
Q1 2023 May 20, 2024	BUY	$7.77 - $12.47 $96,829 - $155,401	12,462 New	12,462 $108,000
Q2 2022 Aug 01, 2022	BUY	$2.21 - $5.56 $1,436 - $3,613	650 Added 5.5%	12,462 $69,000
Q1 2022 Apr 28, 2022	BUY	$5.07 - $13.68 $1,521 - $4,104	300 Added 2.61%	11,812 $62,000
Q4 2021 Jan 20, 2022	BUY	$11.91 - $17.0 $133,534 - $190,604	11,212 Added 3737.33%	11,512 $148,000
Q3 2021 Nov 02, 2021	BUY	$13.21 - $20.91 $3,963 - $6,273	300 New	300 $4,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.